Suppr超能文献

用于检测结直肠腺瘤的免疫化学粪便潜血试验的比较评估

Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.

作者信息

Hundt Sabrina, Haug Ulrike, Brenner Hermann

机构信息

The German Cancer Research Center, Heidelberg, Germany.

出版信息

Ann Intern Med. 2009 Feb 3;150(3):162-9. doi: 10.7326/0003-4819-150-3-200902030-00005.

Abstract

BACKGROUND

Different immunochemical fecal occult blood tests (FOBTs) have been proposed for noninvasive colorectal cancer screening. Large-scale, colonoscopy-based screening studies that allow evaluation of these tests for the detection of precursor lesions are scarce.

OBJECTIVE

To determine and compare performance characteristics of 6 qualitative immunochemical FOBTs for identifying colorectal adenomas among adults who attended screening colonoscopy examinations.

DESIGN

Prospective screening study from January 2006 to December 2007.

SETTING

20 gastroenterology practices in Germany that did screening colonoscopy.

PATIENTS

1319 participants at average risk for colorectal neoplasia who were undergoing screening colonoscopy (mean age, 63 years; 50% men).

MEASUREMENTS

6 different qualitative immunochemical FOBTs were done with stool samples collected before bowel preparation for colonoscopy. Performance characteristics (sensitivity, specificity, predictive values, and likelihood ratios) of tests were measured by comparing test results with findings on colonoscopy. Technicians who read the tests were blinded to colonoscopy results, and colonoscopists were blinded to FOBT results.

RESULTS

Overall, 405 participants (31%) had an adenoma and 130 participants (10%) had an advanced adenoma. Performance characteristics varied widely among tests. For the 2 best-performing tests (immoCARE-C [CAREdiagnostica, Voerde, Germany] and FOB advanced [ulti med, Ahrensburg, Germany]), the sensitivity for detection of advanced adenomas was 25% (95% CI, 18% to 34%) and 27% (CI, 20% to 35%), respectively; specificity was 97% (CI, 95% to 98%) and 93% (CI, 91% to 95%); and the positive likelihood ratio was 3.5 (CI, 2.2 to 5.4) and 2.5 (CI, 1.9 to 3.5).

LIMITATION

The study differed from real-life conditions in that stool samples were not directly dissolved in a buffer-filled vial; instead, a small container was used and stool was frozen before testing.

CONCLUSION

Qualitative immunochemical FOBTs could be an option for future colorectal cancer screening because they showed better performance characteristics for precursor lesions than guaiac-based FOBTs and are practical for mass screening. However, given the large differences in diagnostic performance among tests, careful evaluation of the different test variants is important.

FUNDING

The German Research Foundation (Deutsche Forschungsgemeinschaft) within the framework of a PhD program (Graduiertenkolleg 793).

摘要

背景

已提出不同的免疫化学粪便潜血试验(FOBT)用于非侵入性结直肠癌筛查。基于结肠镜检查的大规模筛查研究稀缺,这类研究能够评估这些试验用于检测前驱病变的情况。

目的

确定并比较6种定性免疫化学FOBT在接受筛查结肠镜检查的成年人中识别结直肠腺瘤的性能特征。

设计

2006年1月至2007年12月的前瞻性筛查研究。

地点

德国20家进行筛查结肠镜检查的胃肠病诊疗机构。

患者

1319名患结直肠肿瘤平均风险的参与者,他们正在接受筛查结肠镜检查(平均年龄63岁;50%为男性)。

测量

在结肠镜检查肠道准备前采集的粪便样本进行6种不同的定性免疫化学FOBT。通过将试验结果与结肠镜检查结果相比较来测量试验的性能特征(敏感性、特异性、预测值和似然比)。解读试验的技术人员对结肠镜检查结果不知情,结肠镜检查人员对FOBT结果不知情。

结果

总体而言,405名参与者(31%)患有腺瘤,130名参与者(10%)患有进展性腺瘤。试验之间的性能特征差异很大。对于表现最佳的2种试验(immoCARE-C [CAREdiagnostica,德国费尔德]和FOB advanced [ulti med,德国阿伦斯堡]),检测进展性腺瘤的敏感性分别为25%(95%CI,18%至34%)和27%(CI,20%至35%);特异性分别为97%(CI,95%至98%)和93%(CI,91%至95%);阳性似然比分别为3.5(CI,2.2至5.4)和2.5(CI,1.9至3.5)。

局限性

该研究与实际情况不同之处在于粪便样本不是直接溶解在装有缓冲液的小瓶中;而是使用一个小容器,在检测前将粪便冷冻。

结论

定性免疫化学FOBT可能是未来结直肠癌筛查的一种选择,因为它们在前驱病变方面比基于愈创木脂的FOBT表现出更好的性能特征,并且适用于大规模筛查。然而,鉴于试验之间诊断性能差异很大,仔细评估不同的试验变体很重要。

资助

德国研究基金会(Deutsche Forschungsgemeinschaft)在博士项目(Graduiertenkolleg 793)框架内提供资助。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验